Cancer Treatment and End-of-Life Care

Journal of Palliative Medicine
Sudha SinhaMikael Segerlantz

Abstract

To study to what extent tumor-specific treatment (chemo- or radiotherapy) was given during the last 30 days in life and to examine how many of the patients were referred to a specialized palliative care unit (PCU), at a low-resource governmental hospital in India. Medical records of adult cancer patients deceased between April 1 and May 31 in 2016, and pediatric cancer patients deceased between April 1 and September 30 in 2016 were collected. Data regarding gender, age at admission, cancer diagnosis, tumor-specific treatment received, referral to the PCU, and date of death, were sampled. A total of 96 patients (52 adults and 44 pediatric patients) were included in the study. In the last 30 days of life, tumor-specific treatment was given to 39 adult patients and 38 pediatric patients. During the last week in life, 26 adult and 25 pediatric patients, respectively, received tumor-specific treatment. Twenty-six adult and 25 pediatric patients, respectively, were referred to the PCU. End-of-life (EoL) tumor therapy was given to a lesser extent among referred patients. Eighty percent of the patients were given tumor-specific treatment near EoL. Half of the patients had been referred for specialized palliative care (SPC).

References

Jul 27, 2000·Journal of the Royal Society of Medicine·D SeamarkC Seamark
Feb 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y OheY Nishiwaki
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Craig C EarleSusan Block
Apr 16, 2003·Annals of Internal Medicine·Ezekiel J EmanuelArlene S Ash
Apr 30, 2005·Journal of Palliative Medicine·T J Iwashyna, N A Christakis
Jul 13, 2006·International Journal of Nursing Practice·Sujatha ShanmugasundaramMargaret O'Connor
Jul 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robin MatsuyamaThomas J Smith
Apr 9, 2008·Journal of Pain and Symptom Management·Elizabeth McDermottDavid Clark
Aug 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Craig C EarleJohn Z Ayanian
Jan 15, 2011·Journal of Pain and Symptom Management·Young Ji BaekEun-Cheol Park
Dec 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph A GreerJennifer S Temel
Jan 17, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Kikuo NakanoShoji Sunada
Oct 26, 2012·The New England Journal of Medicine·Jane C WeeksDeborah Schrag
Dec 6, 2012·Journal of Pain and Symptom Management·David HuiEduardo Bruera
Feb 27, 2013·Indian Journal of Palliative Care·Divya KhoslaSuresh C Sharma
Mar 1, 2015·Journal of the Egyptian National Cancer Institute·Amrallah A MohammedHani M El-Khatib
Apr 2, 2015·Journal of Oncology Practice·William F PirlJennifer S Temel
Apr 29, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joanne WolfeVeronica Dussel
Jul 24, 2015·JAMA Oncology·Holly G PrigersonPaul K Maciejewski
Apr 20, 2016·The Oncologist·Chin-Chia WuChing-Chih Lee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.